"
Electrocardiographic Safety of Daily Hydroxychloroquine 400 mg Plus Azithromycin 250 mg as an Ambulatory Treatment for COVID-19 Patients in Cameroon"
written by Liliane Mfeukeu-Kuate, William Djomo Ngatchou, Mazou Ngou Temgoua, Charles Kouanfack, Daniel Lemoungoum, Joel Noutakdie Tochie, Armel Zemsi, Lauriane Fomete, Skinner Lekelem, Sylvain Zemsi, Joelle Sobngwi, Thierry Ntandzi, Christian Ngongang Ouankou, Yves Wasnyo, Antoinette Tsama Assiga, Jan René Nkeck, Ahmadou Musa Jingi, Magellan Guewo, Eric Walter Pefura Yone, Charlotte Moussi Omgba, Paul Owono Etoundi, Jean Cyr Yombi, Samuel Kingue, Alain Menanga, Jacqueline Ze Minkande, Pierre Ongolo Zogo, Jean Claude Mbanya, Pierre Joseph Fouda, Eugène Sobngwi,
published by
World Journal of Cardiovascular Diseases,
Vol.11 No.2, 2021
has been cited by the following article(s):
|
[1]
|
Doxycycline vs Hydroxychloroquine + Azithromycin in the Management of COVID-19 Patients: An Open-Label Randomized Clinical Trial in Sub-Saharan Africa (DOXYCOV)
Cureus,
2023
DOI:10.7759/cureus.45619
|
|
|
|